IL278575A - - Google Patents

Info

Publication number
IL278575A
IL278575A IL27857520A IL27857520A IL278575A IL 278575 A IL278575 A IL 278575A IL 27857520 A IL27857520 A IL 27857520A IL 27857520 A IL27857520 A IL 27857520A IL 278575 A IL278575 A IL 278575A
Authority
IL
Israel
Application number
IL27857520A
Other languages
English (en)
Other versions
IL278575B1 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of IL278575A publication Critical patent/IL278575A/en
Publication of IL278575B1 publication Critical patent/IL278575B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL278575A 2018-05-21 2020-11-09 Dantrolene formulations and methods of using them IL278575B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862674394P 2018-05-21 2018-05-21
PCT/US2019/033260 WO2019226621A1 (en) 2018-05-21 2019-05-21 Dantrolene formulations and methods of their use

Publications (2)

Publication Number Publication Date
IL278575A true IL278575A (enExample) 2021-01-31
IL278575B1 IL278575B1 (en) 2026-03-01

Family

ID=66821419

Family Applications (1)

Application Number Title Priority Date Filing Date
IL278575A IL278575B1 (en) 2018-05-21 2020-11-09 Dantrolene formulations and methods of using them

Country Status (15)

Country Link
US (1) US20210236467A1 (enExample)
EP (1) EP3796889A1 (enExample)
JP (2) JP7762489B2 (enExample)
KR (1) KR20210011961A (enExample)
CN (1) CN112135605A (enExample)
AU (1) AU2019272577B2 (enExample)
BR (1) BR112020023012A2 (enExample)
CA (1) CA3101093A1 (enExample)
IL (1) IL278575B1 (enExample)
MA (1) MA52707A (enExample)
MX (2) MX2020012464A (enExample)
SG (1) SG11202011121UA (enExample)
UA (1) UA127661C2 (enExample)
WO (1) WO2019226621A1 (enExample)
ZA (1) ZA202006986B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419795A (zh) * 2020-05-09 2020-07-17 上药东英(江苏)药业有限公司 一种注射用丹曲林钠混悬剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017710A1 (fr) 1992-03-10 1993-09-16 Yamanouchi Pharmaceutical Co., Ltd. Preparation pharmaceutique pour administration transcutanee
JPH06263636A (ja) * 1993-03-12 1994-09-20 Kiyoshi Kataoka 脳または高次神経疾患治療剤
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
WO2005013919A2 (en) * 2003-03-04 2005-02-17 Lyotropic Therapeutics, Inc. Treatment using dantrolene
WO2010126818A1 (en) * 2009-04-27 2010-11-04 Usworldmeds Llc Intranasal delivery system for dantrolene
WO2019175761A1 (en) * 2018-03-12 2019-09-19 Orbicular Pharmaceutical Technologies Private Limited Ready to use dantrolene compositions

Also Published As

Publication number Publication date
CA3101093A1 (en) 2019-11-28
CN112135605A (zh) 2020-12-25
MX2020012464A (es) 2021-02-09
KR20210011961A (ko) 2021-02-02
MA52707A (fr) 2021-03-31
AU2019272577B2 (en) 2024-08-08
BR112020023012A2 (pt) 2021-02-02
EP3796889A1 (en) 2021-03-31
JP7762489B2 (ja) 2025-10-30
WO2019226621A1 (en) 2019-11-28
ZA202006986B (en) 2024-04-24
MX2025002392A (es) 2025-04-02
UA127661C2 (uk) 2023-11-22
IL278575B1 (en) 2026-03-01
JP2024023270A (ja) 2024-02-21
US20210236467A1 (en) 2021-08-05
AU2019272577A1 (en) 2020-11-26
JP2021524855A (ja) 2021-09-16
SG11202011121UA (en) 2020-12-30

Similar Documents

Publication Publication Date Title
BR112021012225A2 (enExample)
BR112021008873A2 (enExample)
BR122022006221A2 (enExample)
BR112021000792B8 (enExample)
BR122022015534A2 (enExample)
BR122022002102A2 (enExample)
AT524834A2 (enExample)
AT524874A5 (enExample)
AU2018438767B1 (enExample)
AT524266A2 (enExample)
AT524961A5 (enExample)
BR122022005529A2 (enExample)
BR122022016585A2 (enExample)
BR112020012832A2 (enExample)
BR202018071071U8 (enExample)
BR102018070765A2 (enExample)
BR102018016915A2 (enExample)
BE2018C025I2 (enExample)
BR112020025288A2 (enExample)
BR202018008879U2 (enExample)
BR202018007669U2 (enExample)
BR102018007062A2 (enExample)
BR202018006247U2 (enExample)
BR202018004136U2 (enExample)
BR202018002487U2 (enExample)